Faisal Suba, MD
Psychiatry · Las Vegas, NVNPI 1598965998
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,008 of the $14,849 with a category attached, or 67.4%. 30 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 35.8% of the total. Among psychiatry clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 525 payments — averaging $28.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$5K
- Neurocrine Biosciences, Inc.$2K
- AbbVie$2K
- Sunovion Pharmaceuticals Inc.$1K
- Johnson & Johnson$865
- Alkermes, Inc.$827
- plus $4K from 24 others
Across 1 payment — averaging $3500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alkermes, Inc.$4K
What the payments were for
- Speaking & faculty fees$4,78132%
- Food & beverage$10,00867%
- Education$600%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 100 | $5,314 |
| Neurocrine Biosciences, Inc. | 53 | $1,595 |
| AbbVie(2 entities) | 101 | $1,564 |
| Sunovion Pharmaceuticals Inc. | 27 | $1,157 |
| Johnson & Johnson | 44 | $865 |
| Alkermes, Inc. | 32 | $827 |
| Teva Pharmaceuticals USA, Inc. | 31 | $815 |
| E.r. Squibb & Sons, L.L.C. | 13 | $406 |
| Axsome Therapeutics, Inc. | 14 | $390 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $358 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 23 | $268 |
| Almatica Pharma LLC | 14 | $218 |
| Lundbeck LLC | 12 | $203 |
| Vanda Pharmaceuticals Inc. | 9 | $198 |
| Corium, LLC | 7 | $125 |
| Bausch Health US, LLC | 5 | $97 |
| Sage Therapeutics, LLC | 4 | $67 |
| Ironshore Pharmaceuticals Inc. | 2 | $48 |
| Shire North American Group Inc | 3 | $48 |
| Supernus Pharmaceuticals, Inc. | 3 | $45 |
| Idorsia Pharmaceuticals US Inc | 3 | $45 |
| Brainsway USA Inc | 1 | $32 |
| Indivior Inc. | 1 | $32 |
| Bioxcel Therapeutics, Inc. | 2 | $30 |
| Tris Pharma Inc | 1 | $22 |
| Acadia Pharmaceuticals Inc | 1 | $19 |
| Neuronetics, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $15 |
| OWP Pharmaceuticals, Inc. | 1 | $15 |
| Medtronic | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABILIFY MAINTENA$3,859
- LATUDA$840
- INGREZZA$738
- ARISTADA$500
- LYBALVI$498
- VRAYLAR$348
- COBENFY$145
- ARISTADA INITIO$125
- UZEDY$116
- REXULTI$115
How this compares
$14,849 in reported general payments places this provider in the 95th percentile of 243 psychiatry providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 24 | $40,491 |
| Divalproex Sodium ErDivalproex Sodium | 23 | $4,424 |
| Divalproex Sodium | 32 | $3,471 |
| Quetiapine Fumarate | 75 | $2,432 |
| Paliperidone ErPaliperidone | 13 | $1,865 |
| Olanzapine | 44 | $1,686 |
| Ziprasidone Hcl | 14 | $1,534 |
| Aripiprazole | 28 | $1,462 |
| Lurasidone Hcl | 23 | $1,422 |
| Risperidone | 63 | $1,245 |
| Sertraline Hcl | 59 | $1,073 |
| Clonazepam | 125 | $855 |
| Mirtazapine | 59 | $624 |
| Fluoxetine Hcl | 28 | $556 |
| Buspirone Hcl | 36 | $505 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $5,314 | $40,49124 claims |
| Almatica Pharma LLCSertraline Hcl | $218 | $1,07359 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 243 psychiatry providers in Nevada.
Other psychiatry in Las Vegas
- Jelena KunovacLas Vegas$1.2M
- John AnooshianLas Vegas$836K
- Sam ZandLas Vegas$410K
- Aaron RitterLas Vegas$173K
- Mustafa RawafLas Vegas$166K
- Dylan WintLas Vegas$86K
- Mujeeb ShadLas Vegas$55K
- Dax WolfordLas Vegas$29K
- Ejine OkoroaforLas Vegas$13K
- John VallesLas Vegas$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.